STOCK TITAN

Genelux Corp - GNLX STOCK NEWS

Welcome to our dedicated news page for Genelux (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genelux's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genelux's position in the market.

Rhea-AI Summary
Genelux (GNLX) reported fourth quarter and full year 2023 financial results, highlighting active enrollment in pivotal Phase 3 trials for platinum resistant ovarian cancer and advancements in lung cancer trials. The company holds $23.2 million in cash and investments. With ongoing clinical trials, Genelux aims to enhance cancer treatment options and offer hope to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.51%
Tags
-
Rhea-AI Summary
Genelux Corporation (GNLX) initiates pivotal Phase 3 study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer. The Phase 2 trial demonstrated clinical reversal of platinum resistance and refractoriness, meeting the primary endpoint of objective response rate with durable responses. The FDA has granted Fast Track designation for the development program of Olvi-Vec for the treatment of patients with platinum resistant/refractory ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
-
Rhea-AI Summary
Genelux Corporation (NASDAQ: GNLX) announced the appointment of Lourie Zak as Chief Financial Officer and an extended clinical focus on systemic administration in small cell lung cancer. The company reported $29.9 million in cash and equivalents for the third quarter of 2023, highlighting pipeline advancements and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.61%
Tags
Rhea-AI Summary
Genelux Corporation grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
none
-
Rhea-AI Summary
Genelux Corporation to present corporate overview at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.69%
Tags
conferences
-
Rhea-AI Summary
Genelux Corporation appoints Lourie S. Zak as Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.01%
Tags
none
Rhea-AI Summary
Genelux Corporation announces financial results for Q2 2023 and provides business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
-
Rhea-AI Summary
Genelux Corporation will be participating in BTIG’s Virtual Biotechnology Conference 2023, where Thomas Zindrick, the President, CEO, and Chairman of the company, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat with Kaveri Pohlman, PhD, BTIG Biotechnology Analyst.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
conferences
-
Rhea-AI Summary
Genelux Corporation announces two key management promotions and two new additions to its leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.77%
Tags
management
Rhea-AI Summary
Genelux Corporation announces positive results from Phase 1 trial of Olvi-Vec in patients with malignant pleural effusion. The trial showed safety, feasibility, and immune activating effects of Olvi-Vec. Median overall survival was 19.5 months for all patients and 22 months for patients with malignant pleural mesothelioma. No dose-limiting toxicities or dose de-escalations were observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
Genelux Corp

Nasdaq:GNLX

GNLX Rankings

GNLX Stock Data

110.69M
19.87M
22.37%
21.64%
7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Westlake Village